Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Cixutumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Cixutumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Cixutumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Cixutumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Cixutumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Cixutumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Cixutumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Cixutumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Cixutumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Cixutumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Cixutumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Cixutumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Cixutumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cixutumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cixutumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Cixutumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Cixutumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Cixutumumab. |
| Equol | Equol may increase the thrombogenic activities of Cixutumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Cixutumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Cixutumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Cixutumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Cixutumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Cixutumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Cixutumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Cixutumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Cixutumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Cixutumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Cixutumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Cixutumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Cixutumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cixutumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Cixutumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Cixutumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Cixutumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cixutumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cixutumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Cixutumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cixutumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Cixutumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Cixutumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Cixutumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cixutumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cixutumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Cixutumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cixutumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cixutumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cixutumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cixutumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Cixutumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Cixutumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Cixutumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cixutumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cixutumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Cixutumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Cixutumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Cixutumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Cixutumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Cixutumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Cixutumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Cixutumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Cixutumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Cixutumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Cixutumumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Cixutumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Cixutumumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Cixutumumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Cixutumumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Cixutumumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Cixutumumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Cixutumumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Cixutumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Cixutumumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Cixutumumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Cixutumumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Cixutumumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Cixutumumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Cixutumumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Cixutumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Cixutumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Cixutumumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Cixutumumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Cixutumumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Cixutumumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Cixutumumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Cixutumumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Cixutumumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cixutumumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Cixutumumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Cixutumumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Cixutumumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Cixutumumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Cixutumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Cixutumumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Cixutumumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Cixutumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cixutumumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Cixutumumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Cixutumumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Cixutumumab. |